The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - Bristol-Myers Squibb; Celgene; Janssen; Merck; Novartis; Onyx; Takeda
Consulting or Advisory Role - Bristol-Myers Squibb; Celgene; Janssen; Merck; Novartis; Onyx; Takeda
Research Funding - Onyx; Takeda
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Celgene; Janssen; Merck; Novartis; Onyx; Takeda
 
Research Funding - Sanofi (Inst)

A phase Ib dose escalation trial of isatuximab (SAR650984, anti-CD38 mAb) plus lenalidomide and dexamethasone (Len/Dex) in relapsed/refractory multiple myeloma (RRMM): Interim results from two new dose cohorts.
 
Ravi Vij
No Relationships to Disclose
 
Nikoletta Lendvai
No Relationships to Disclose
 
Thomas G. Martin
No Relationships to Disclose
 
Rachid C. Baz
Consulting or Advisory Role - Celgene
Research Funding - Bristol-Myers Squibb; Celgene; Karyopharm Therapeutics; Millennium; Sanofi
 
Frank Campana
Employment - Sanofi
Stock and Other Ownership Interests - Sanofi
 
Florent Mazuir
Employment - Sanofi
 
Eric Charpentier
Employment - Sanofi
 
Don M. Benson
Research Funding - Sanofi